Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Linda Knutsson

Professor

Default user image.

Simultaneous Preclinical Positron Emission Tomography-Magnetic Resonance Imaging Study of Lymphatic Drainage of Chelator-Free Cu-Labeled Nanoparticles

Författare

  • Renata Madru
  • Michael Budassi
  • Helene Benveniste
  • Hedok Lee
  • S David Smith
  • David J Schlyer
  • Paul Vaska
  • Linda Knutsson
  • Sven-Erik Strand

Summary, in English

BACKGROUND: Hybrid positron emission tomography (PET)-magnetic resonance imaging (MRI) systems have been taken in use as new clinical diagnostic tools including detection and therapy planning of cancer. To reduce the amount of contrast agents injected in patients while fully benefitting both modalities, dual-modality probes are required.

MATERIAL AND METHODS: This study was first aimed at developing a hybrid PET-MRI probe by labeling superparamagnetic iron oxide nanoparticles (SPIONs) with 64Cu using a fast and chelator-free conjugation method, and second, to demonstrate the ability of the agent to target sentinel lymph nodes (SLNs) in vivo using simultaneous PET-MRI imaging.

RESULTS: High labeling efficiency of 97% produced within 10-15 min was demonstrated at room temperature. 64Cu-SPIONs were chemically stable in mouse serum for 24 h and after intradermal injection in the hind paw of C57BL/6J mice, demonstrated specific accumulation in the SLN. Simultaneous PET-MRI clearly demonstrated visualization of 64Cu-SPIONs, in dynamic and static imaging sequences up to 24 h after administration.

CONCLUSION: The use of a single hybrid probe and simultaneous hybrid imaging provides an efficient, complementary integration of quantitation and is expected to improve preoperative planning and intraoperative guidance of cancer treatments.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • MR Physics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Forskningsgruppen för Systemisk strålterapi

Publiceringsår

2018-08

Språk

Engelska

Sidor

213-220

Publikation/Tidskrift/Serie

Cancer Biotherapy & Radiopharmaceuticals

Volym

33

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Mary Ann Liebert, Inc.

Ämne

  • Cancer and Oncology
  • Radiology, Nuclear Medicine and Medical Imaging
  • Other Physics Topics

Status

Published

Forskningsgrupp

  • MR Physics
  • Systemic Radiation Therapy Group

ISBN/ISSN/Övrigt

  • ISSN: 1557-8852